Anavex Life Sciences Corporation (AVXL) Options

Good points Bourbon. I am certainly open to that as well. Missling is strong in the financial aspects and I do think any partnerships or structures like you mentioned will benefit shareholders. I keep reminding myself that he is also a large shareholder himself. Good comment.

Lacey, you are dead-on. Within two years of approval, Anavex will be at an operating profit run rate $300 million per month or $3.6 Billion for 2-73 only. MC will be in the $40 Billion range.

TGD has stated strongly and emphatically that Anavex is NOT for sale and that is why!!!


Anavex Now ... Right Now ... Anavex for Everyone!!!

Wow, this POS can't even reach $9.

I don't think you could buy Anavex for $120. a successful bid would be north of $500, and still a quarter of what its worth 5 years out.

Disagree: If they were bought out it would have to be early and with "silly" money and ask a CEO if he would be willing to tell his board that he wants to throw that much money at a young biotech. If that does not happen Anavex will quickly become so highly valued that a buyout is doubtful.

Remember Genentech? Did a very lucrative partnership, then 10 years later was bought out at $46 billion [roughly $100 billion in today's dollars] for the remaining shares.

The buyer? Roche.

The company George keeps saying is interested.

coincidentally $100 billion is not too far off from the $1249 share goal.

Minimum I would hope that the $120 stock would get bought out at $250.

Otherwise it would have made the wait seem not so worthwhile.

And do the buyout as a share swap with a high dividend big pharma so no capital gains and div income for life.

Not cash.

But staying independent to $1249 is better, then sell at $2000

True. The optics also strongly suggest, imo, that Missling understands the monstrous opportunity afforded Anavex in the CNS space and the best way to "maximize shareholder value" is to retain as much ownership as possible while executing a plan that protects and maximizes profits.
Yes, a partnership is going to happen. Makes sense but being bought out entirely? If they were bought out it would have to be early and with "silly" money and ask a CEO if he would be willing to tell his board that he wants to throw that much money at a young biotech. If that does not happen Anavex will quickly become so highly valued that a buyout is doubtful. It is still a long ways out but try putting value on a therapeutic that prevents the onset of a worldwide disease like AD. Staggering.

"What is HC Wainwright’s Estimate for AVXL Q1 Earnings?"
MarketBeat News on Feb 21st, 2025

Anavex Life Sciences Corp. (NASDAQ:AVXL – Free Report) – Research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Anavex Life Sciences in a research report issued on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju anticipates that the biotechnology company will earn ($0.18) per share for the quarter. HC Wainwright has a “Buy” rating and a $42.00 price objective on the stock.
The consensus estimate for Anavex Life Sciences’ current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Anavex Life Sciences’ Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.66) EPS.
Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.03.
Separately, D. Boral Capital reaffirmed a “buy” rating and set a $46.00 price target on shares of Anavex Life Sciences in a research report on Wednesday, February 12th.

Institutional Investors Weigh In On Anavex Life Sciences
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AVXL.
Squarepoint Ops LLC grew its holdings in Anavex Life Sciences by 304.9% during the 4th quarter. Squarepoint Ops LLC now owns 67,627 shares of the biotechnology company’s stock valued at $726,000 after buying an additional 50,924 shares in the last quarter.
ProShare Advisors LLC grew its holdings in Anavex Life Sciences by 31.0% during the 4th quarter. ProShare Advisors LLC now owns 25,147 shares of the biotechnology company’s stock valued at $270,000 after buying an additional 5,958 shares in the last quarter.
Deutsche Bank AG grew its holdings in Anavex Life Sciences by 63.3% during the 4th quarter. Deutsche Bank AG now owns 64,544 shares of the biotechnology company’s stock valued at $693,000 after buying an additional 25,024 shares in the last quarter.
D. E. Shaw & Co. Inc. purchased a new stake in Anavex Life Sciences during the 4th quarter valued at approximately $1,129,000.
Finally, Cetera Investment Advisers purchased a new stake in Anavex Life Sciences during the 4th quarter valued at approximately $150,000. 31.55% of the stock is owned by hedge funds and other institutional investors.

Pogue - Your criticisms of Missling’s speech (and I would add his writing) are spot on. I have been saying this for a decade. However, there are some deeper truths. Among them are: 1) Missling is who he is and he’s clearly not going to change. He is either oblivious to any criticism or doesn’t care. He’s made millions doing exactly what he does and is laughing all the way to the bank. Either way, he’s not going to change. 2) Nothing that has ever been written on this message board has ever changed anybody’s mind about anything. Not a single person who posts here has any interest in being open minded much less admitting to possibly being wrong. 3) At this point Blarcamesine will either be approved in Europe or not. Nothing that is said here will change the final outcome.

It's going to be hard for anyone to refute the easy to see fact that Blarcamesine slows/stops the shrinking of the brain caused by AD!  

I am not a CEO conducting business in those countries.

How has your French, Spanish, German, Mandarin, or Dutch improved?

Merica!

Article doubting current treatment of ALZ from a poster on I-V.

https://news.uchicago.edu/where-has-alzheimers-research-gone-wrong

I don't know how much the authors know about what we're doing. I believe that if they looked at slowing brain shrinking they'd agree it's a step in the right direction, even if it's not curative.

Gary

If Anavex were bought out @$120 per share after EMA approval, that would represent less value than what Karuna received for its schizophrenia drug while awaiting FDA approval.

When it comes to a pre-revenue company, I spent decades in IMGN and watched the price rise and fall based on a variety of news events. Even an approval ment little when monetized, instead of waiting for growing revenue from the partnered who licensed the approved drug, Kadcyla.

Everything changed with approval of a wholly owned drug, but sadly in IMGN's case they took a buyout, that was quite profitable to all, but many believe they'd have gone much further had they remained independent.

I believe that the Analyst's $40+ targets anticipate European approval, but they're only a starting point. At that point I believe we'll not only add several more analysts, but I suspect their targets will be into triple digits. Of course if like IMGN management choose a buyout, then we may be looking at somewhere in the $80 to $120 range. If they wait, it could go far higher. Sadly, too many companies don't wait, often Institutional ownership is happy with the big payoff, rather than taking the longer, but larger gain.

Gary

Well dang, thanks for the pointing that out. I still think we’re #1!

Looks like a Low Volume Day 714,000 shares traded. Of that total 64,000 were MOC order. The only other notable bit of volume was when we hit low for the day. $8.63 Then someone bought 34,000 shares.
John k9uwa

Great find!

Except for an oddity near the bottom of the list, it is in alphabetical order.  That is why Anavex is at the top. 

I just emailed her the link to the “10 biotech companies to watch in 2025” that has Anavex at the top of the list!

https://www.labiotech.eu/best-biotech/biotech-companies-2025/

The only thing that will convince "the public" about how good Blarcamesine is, is approval and the resulting availability.
What you are talking about is PR campaign which will have a short term impact on the SP at best.

"shouldn’t Anavex & Missling be doing this" perhaps it is better coming from one our knowledgeable posters and stock owners than it would be from Missling.

BIG THANKS POWER. Yes I read the article and yes I read all the comments below the article.
John k9uwa

"Awaiting blarcamesine as an approved drug. Everyone will benefit." I can see it now. Eventually all us Old Coots will take a blarcamesine daily the same as we now do with a baby aspirin. Preventative Medicine. And yes I do think we will see some increase in AVXL price once we pass Clock Stop One.

And to "DoTheRightThing" re: your comments about 10 years of pricing of Anavex. I am thinking that ALL of us who have played the game with AVXL are Way ahead due to trading in one fashion or another... A few days ago one of our posters said once he took out enough to buy a new car. I will say back in 2021 I took out enough to buy another Residential Rental property. That was #14 for us.
John k9uwa

Ever hear of hockey stick?

By the way, nobody is putting a gun to a patient’s head to try either Leqembi or Kisunla
You realize losing your mind is a death sentence. People will try anything.
Ease of use Blarcamesine will be a Godsend.

re: but let’s be thankful that there are patients who are seeing even modest benefits with the currently approved treatments.

Some EMA researchers have refuted the mabs' claim of any significant, noticeable, clinical efficacy....implying that claims were made by others too closely tied to the pharmas to be reliable sources.

Maybe Blarcamesine will prove to be superior and maybe not ...

Bio*4, just to set your mind at ease, Blarcamesine has proven to be superior and will be approved by EMA in a matter of months.

fda will follow once DJT and RFK, Jr. hear about it.

Where have you been? People have been saying the same thing over and over again since the beginning.

The article on Fox “News” was reporting on a study by the Washington University School of Medicine in St. Louis that was recently published in the Alzheimer’s Association journal. I’m not sure why you have a problem with that.

By the way, nobody is putting a gun to a patient’s head to try either Leqembi or Kisunla.

Maybe Blarcamesine will prove to be superior and maybe not, but let’s be thankful that there are patients who are seeing even modest benefits with the currently approved treatments.

Maybe we should put fliers on telephone poles announcing the benefits of blarcamesine.

"melissa.rudy@fox.com"--also sent this Fox news reporter and informed her about Blarcamesine---perhaps more here should do the same-----The squeaky wheel gets the oil" !!!!

While you are thinking about "all the people on statins now," Bourbon, you might also want to take a quick look at the February edition of PTAD, which includes a paper showing a greater propensity of statin users to develop AD, particularly those with the wild type gene. To the extent that 2-73 and/or 3-71 are shown to act (to some significant degree) as preventative, that could add a very large target market.

It's been well over a decade only three things will help approvals partnership or a buyout everything else is useless word salad

As Mayomobile has pointed out, the EMA is a better fit for an AD drug approval for blarcamesine

you should have stopped at the first sentence, which was spot on. the rest was politics, but I will let it slide.

We'll NEVER hear about that again.

As Mayomobile has pointed out, the EMA is a better fit for an AD drug approval for blarcamesine. I don't at all buy that the FDA is corrupt. However, it is also lucky that we're dealing with the EMA now rather than the FDA which is, like most of the civil government, engulfed in a paralytic chaos.

Anavex planned to begin its Parkinson's Phase 3 trial by late January, which has clearly slipped. I think the issue is at the FDA end. I think they are presently a mess.

Where's that PDD trial news?

Didn't you hear, it starts right after the rare disease trial gets going.

A money heavy partner could change that pretty fast.

An EMA approval is what will change things. It will be big news.

I hope you’re correct.

See how Anavex Life Sciences Corp (and its shareholders) will benefit when this or some other prodromal test for Alzheimer's becomes a standard medical practice, used on all people starting in their middle ages.

yes easy effective testing will sell 273, think of all the people on statins now. this will become a standard test for middle age. all funnelling people into the one safe easy and effective treatment for early alzheimers

My Mother dreamed in five different languages...
AND was a District Teacher's Teacher for 30+ years.
I have trouble at times with one, English.
Language is not an issue and your bigotry is poorly founded..
Presentation perhaps is.
Misslling is NOT a Top Gear presenter.

You have ZERO evidence of this assertion but it was wise of Missling to avoid any conflicts of interest with the Big Pharma influenced FDA, and instead work with the European Medicines Agency (EMA) to submit Blarcamesine trial data for Anavex's initial commercial approval.

It would be better if he invested his time in an English-speaking and effective presentation class for (arrogant) Germans.

Who will fire him? BODs are in his pocket, most of them are his college buddies. He, CMO and accountant should have been fired after rett failure.

That’s wonderful, but shouldn’t Anavex & Missling be doing this?

Sent an email to Melissa and informed her about Blarcamesine.

Her email address is:

melissa.rudy@fox.com

New Dr Missling post - https://www.linkedin.com/posts/christopher-missling-phd-18924a_brainhealth-mentalhealth-anavex-activity-7298359518164336640-CK68/?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAk2y8EBSCkG-CZG-fmrfHJbdOROejFU-zA

Why am I here? I’ve asked myself that same question many times over the past 10 years.

While I have no association with kund, I am pleased to see how much his written english has improved over these past several years. Unfortunately, the same cannot be said about our bumbling CEO’s spoken english. He still is hard to listen to 10 years later—embarrassing.

Why are you here Guzzi?

Crazy that folks can’t understand how great A2-73 is and that Anavex EMA approval at >83% chance is an almost certainty!!!